Idogen’s cell therapy product successfully produced by GMP-certified manufacturing partner
Idogen AB (Nasdaq First North Growth Market: IDOGEN) has today announced that the manufacturing process for the company’s tolerogenic cell therapy has been successfully established at its collaboration partner Radboud University Medical Center in the Netherlands. The next step is to qualify the process for the submission of an application for commencement of the first clinical trial, which is expected to be able to start in H1 2021. Idogen’s tolerogenic cell therapy is based on dendritic cells, a type of white blood cell that plays a key role in the immune system’s ability to